Agentic AI in Regulated Manufacturing: Where Autonomy Stops
An agent is a model that plans a sequence of actions and executes them against real systems, rather than returning text.

In Short
- Forget the marketing taxonomy of assistants, copilots and agents.
- There is real value on the safe side of the line.
- Batch release and material disposition are out: 21 CFR 211.22 and EU GMP place them with the quality unit and, in the EU, a named Qualified Person.
In an unregulated business that is mostly an efficiency question. In a GMP plant it is a compliance question, because a surprising proportion of the actions worth automating are signed decisions with a named accountable person attached. This guide draws the line: what an agent can safely do in regulated manufacturing, what it must never do, and how to document the boundary so it survives an inspection.
The distinction that matters: reversible versus signed
Forget the marketing taxonomy of assistants, copilots and agents. The only classification that matters on a regulated site is whether an action is reversible and unsigned, or whether it constitutes a regulated decision.
More on the distinction that matters: reversible versus signed
Assembling a draft, gathering evidence, opening a record in draft state, populating a form, scheduling a reminder, running a query — reversible, unsigned, safe to automate. Approving a document, releasing a batch, closing a CAPA, dispositioning material, changing a specification, overriding a tolerance, signing anything — regulated decisions with a legally accountable human behind them. An agent may prepare all of the second category. It may complete none of it.
Safe agentic work: preparation, chasing and assembly
There is real value on the safe side of the line. An agent can watch for a deviation with no investigation started after 24 hours and open the draft with the evidence attached.
More on safe agentic work: preparation, chasing and assembly
It can assemble the annual product review from live batch, deviation, OOS, complaint and stability data and present it for the QP to challenge. It can monitor regulatory publications, identify the changes touching your products, and raise a proposed change control. It can score supplier performance continuously and flag certificates approaching expiry. It can rank a sales worklist, draft the customer email, and prepare the inspection binder. Each of those ends with a human opening something that is already 80% done — which is where the hours actually are.
Forbidden actions — and why the list is short but absolute
Batch release and material disposition are out: 21 CFR 211.22 and EU GMP place them with the quality unit and, in the EU, a named Qualified Person. Electronic signature is out: under 21 CFR Part 11 a signature is bound to an individual with re-authentication and a stated meaning, and a model has no identity to bind.
More on forbidden actions — and why the list is short but absolute
CAPA closure and effectiveness verification are out, because both are judgements about whether a risk has actually been removed. Specification and tolerance change is out: that is change control, with impact assessment and approval. Audit trail modification is not merely forbidden but architecturally impossible on any system worth buying. The list is short. Its shortness is the point — everything else is available for automation, so there is no reason to argue about these five.
The failure modes to design against
Three specific risks separate a well-built agent from a liability. Confident error: an agent asserting something false with the same tone it uses for truth — mitigated by grounding every output in a cited record and showing the source.
More on the failure modes to design against
Version blindness: acting on a superseded procedure or an expired specification — mitigated by making effectivity a first-class constraint, not a field the model happens to read. Silent scope creep: an agent given a broad goal taking a path nobody anticipated — mitigated by defining permitted actions as an explicit allow-list rather than by instructing a model not to do things. Prompt text is not a control. Permissions are a control.
Documenting the boundary for an inspector
You need four things on file, and they are the same four regardless of framework. One: an intended-use statement per agent capability, narrow enough to be tested.
More on documenting the boundary for an inspector
Two: a risk assessment under GAMP 5 Second Edition classifying the capability as supporting and non-decision-making, with the consequence of a wrong output documented. Three: evidence of human review in the audit trail — every agent output recorded as accepted, edited or rejected, with the person and timestamp. Four: the permitted-action allow-list itself, held under change control, so you can show an inspector what the system is technically incapable of doing rather than arguing about intent. Under the EU AI Act, that package is broadly what documented purpose, human oversight and traceability require.
Questions to put to any vendor selling agents into your plant
Six questions, and the answers should be immediate. What is the technical list of actions your agent can take — not the policy, the list?
More on questions to put to any vendor selling agents into your plant
Can the agent sign, release or dispose, under any configuration? How is effectivity enforced when the agent reads a procedure? Does the audit trail distinguish a human-authored entry from an accepted AI draft? Where does inference run, and is our data used for training? What intended-use and risk documentation do you supply for validation? A vendor who answers the first question with 'it's very capable' is selling you an unbounded system, and an unbounded system in a GxP environment is a finding waiting for an inspection date.
Questions
Is agentic AI allowed under GMP?
Nothing prohibits AI as such. What the frameworks require is that regulated decisions are made by authorised, accountable people, that computerised systems are validated for their intended use, and that records are attributable and traceable. Agents that prepare work and stop at the signature satisfy all three. Agents that decide do not.
Can an agent open and populate a deviation on its own?
Yes — opening a draft record is reversible and unsigned. It can attach the evidence, propose root-cause lines and route it to the right owner. Classification, root cause and closure are human decisions signed on the record.
What about the EU AI Act?
For assistive, human-in-the-loop use in manufacturing quality, the practical requirements are a documented purpose, meaningful human oversight, logging and traceability of outputs. If you already hold GxP validation documentation and an audit trail recording human review, most of that package already exists.
How do we stop an agent acting on an outdated SOP?
Make effectivity a system constraint rather than a prompt instruction. The agent should only be able to retrieve the effective revision for the site and date in question, and should cite the revision in its output so a reviewer can see immediately which document it used.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
- Who decides, and who may not
- Supplier to finished bulk
- Test, review, investigate
- Packs, serialisation and recall
Plus Evidence map and four worksheets.
Get the pharmaceutical guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.

Keep reading
AI in Manufacturing Execution: What It Does Today, and What It Doesn't
EU AI Act (Regulation 2024/1689) for Regulated Manufacturers
AI and 21 CFR Part 11: Where AI Fits in Regulated Records
Predetermined Change Control Plans (21 U.S.C. 360e-4) for Medical Devices
Supplement Allergen Control: Validated Cleaning and Labelling
CAR T Cell Manufacturing Readiness: Chain of Identity and Release